37 studies found for:    " January 07, 2009":" February 06, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed
Has Results
A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC310911 75 mg twice daily;   Drug: TMC310911 150 mg twice daily;   Drug: TMC310911 300 mg twice daily;   Drug: TMC310911 300 mg once daily;   Drug: Ritonavir 100 mg twice daily;   Drug: Ritonavir 100 mg once daily
22 Completed
Has Results
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
Condition: Human Immunodeficiency Virus-1
Intervention: Drug: maraviroc
23 Completed Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults
Condition: HIV Infections
Intervention: Drug: Structured treatment interruption
24 Completed
Has Results
Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
Condition: HIV Infections
Interventions: Drug: Nevirapine XR;   Drug: Nevirapine IR
25 Completed Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
Condition: HIV Infections
Interventions: Drug: Chloroquine;   Drug: Placebo
26 Completed
Has Results
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Condition: HIV-1 Infection
Intervention: Drug: Rescriptor
27 Completed TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
Conditions: Tuberculosis;   HIV
Intervention: Drug: TMC207
28 Completed
Has Results
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
Condition: HIV-1 Infections
Interventions: Drug: Raltegravir;   Drug: Darunavir/Ritonavir
29 Completed TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.
Conditions: HIV;   Pharmacokinetics
Intervention: Drug: TMC125
30 Terminated A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
Condition: HIV-1
Intervention: Drug: No drug will be administered
31 Completed
Has Results
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1
Condition: HIV-1
Interventions: Drug: UK-453, 061;   Drug: EFV +TVA
32 Completed PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Condition: HIV-1
Intervention: Drug: TMC558445; TMC310911; Darunavir; Placebo
33 Terminated
Has Results
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1;   Drug: UK-453,061 Dose 2;   Drug: Etravirine
34 Completed
Has Results
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal vaccine GSK1024850A;   Biological: Tritanrix-HepB/Hib;   Biological: measles;   Biological: Rotarix;   Biological: Local OPV
35 Completed Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629
Condition: HIV-I
Intervention: Drug: TMC114; TMC41629
36 Unknown  A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe
Condition: AIDS-Related Kaposi's Sarcoma
Interventions: Drug: abacavir/3TC/zidovudine;   Drug: abacavir /3TC plus ritonavir boosted lopinavir
37 Recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate

Show previous page of results Previous Page (1-20) Studies Shown (21-37) Next Page
Indicates status has not been verified in more than two years